Plasma-Based TMB May Predict Pembrolizumab Response in NSCLC
Published: Tuesday, Mar 24, 2020
Charu Aggarwal, MD, MPH
Plasma-based tumor mutational burden (TMB) has potential as a predictive biomarker for responses to immunotherapy or immunotherapy combinations in patients with non–small cell lung cancer (NSCLC), explained Charu Aggarwal, MD, MPH.
... to read the full story